Last updated on April 2018

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)


Brief description of study

The aim of this study is to improve the chance of cure for people with higher risk Hodgkin lymphoma. The purpose of the Phase I study is to test any good and bad effects of the study drug called Nivolumab when combined with ABVD for the front-line treatment of HL.The purpose of this Phase II study is to test whether including nivolumab in treatment for untreated Hodgkin lymphoma can improve the chance of cure for patients with abnormal PET scans after 2 cycles of ABVD.

Clinical Study Identifier: NCT03033914

Contact Investigators or Research Sites near you

Start Over

Alison Moskowitz, MD

Memorial Sloan Kettering Westchester
Harrison, NY United States
  Connect »